Breaking Finance News

Bankhaus Lampe KG announced Bayer (ETR:BAYN), raising its target price to 103.00EUR earlier today

In a statement issued on 9/28/2016 Bankhaus Lampe KG increased the stock price target of Bayer (ETR:BAYN) to 103.00EUR stating a potential upside of 0.16%.

Previously on 9/27/2016, Commerzbank AG released a statement for Bayer (ETR:BAYN) raised the target price from 0.00EUR to 118.00EUR. At the time, this indicated a possible upside of 0.32%.

Only yesterday Bayer (ETR:BAYN) traded 0.00% even at 89.15EUR. BAYN’s 50-day average is 0.04EUR and its 200-day moving average is 0.03EUR. With the last stock price close up -4.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 215

Recent Performance Chart

Bayer (ETR:BAYN)

Bayer has a with a one year low of 0.03EUR and a one year high of 0.04EUR The company’s market cap is currently 0 EUR.

About Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.